Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment
- 3 April 2008
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (7) , 1012-1022
- https://doi.org/10.1016/j.intimp.2008.03.005
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccineVaccine, 2007
- Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody reponses to a Plasmodium falciparum blood-stage vaccineVaccine, 2007
- IL-4-induced AID expression and its relevance to IgA class switch recombinationBiochemical and Biophysical Research Communications, 2007
- Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized TrialPLoS Clinical Trials, 2006
- Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan ChildrenPLoS Clinical Trials, 2006
- Immunity to RecombinantPlasmodium falciparumMerozoite Surface Protein 1 (MSP1): Protection inAotus nancymaiMonkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory ActivityInfection and Immunity, 2006
- Reduced Protective Efficacy of a Blood-Stage Malaria Vaccine by Concurrent Nematode InfectionInfection and Immunity, 2006
- The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent MechanismInfection and Immunity, 2001
- Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720Vaccine, 1997
- Human immune response to MSP-1Parasitology Today, 1996